Targeted therapies for rare lung diseases
Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled formulations of approved medicines to treat rare respiratory diseases, including idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases. Its pipeline includes AP01 (inhaled pirfenidone), AP02 (inhaled nintedanib), and AP03 (a fixed-dose combination of both), all designed to deliver effective therapy directly to lung tissue to enhance efficacy and reduce systemic side effects. Avalyn completed its IPO in May 2026.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountSep 2023
Apr 2020
May 2017
Aug 2015
Create a free account to see which investors have funded this company.
Create Free Account
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
Healthcare company applying technology to drug development by building nimble biotech subsidiarie...
Neuralink is building a brain-computer interface for medical needs and greater human potential.
